Samumed, a private biotech that's racked up the heady valuation of $12 billion, just raised an additional $438 million. The company is developing a pipeline of what could be revolutionary treatments ...

Founded in 2008, Samumed has spent most of its lifetime working under the radar. It came out of the shadows in 2016 with a war chest of $220 million drawn from investors including Ikea’s private ...

SAN DIEGO--(BUSINESS WIRE)--Samumed, LLC, a leader in tissue regeneration, announced today preliminary analysis of efficacy data from its Phase II AGA trial, in which one of the dosage arms, compared ...

Samumed, LLC has raised $438 million, the San Diego regenerative medicine company said Monday. The new financing round brings the total to more than $650 million since Samumed’s founding, valuing the ...

SAN DIEGO, May 22, 2020 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today the publication of results from the Phase 2a trial of lorecivivint, an investigational CLK/DYRK1A inhibitor that modulates the ...

SAN DIEGO--(BUSINESS WIRE)--A Phase 1 study of Samumed’s investigational drug SM04690 demonstrated potential for cartilage regeneration, as well as improvements in pain and function associated with OA ...

San Diego, CA--November 1, 2016 - Samumed, a leader in tissue regeneration, today announced it has been selected to feature seven presentations in five different therapeutic areas at the 2016 American ...

Samumed has raised $438 million with a $12 billion valuation. Samumed is a leader in medical research and development for tissue-level regeneration. They have a biotechnology platform based on small ...

A San Diego-based life sciences company specializing in regenerative medicine has raised nearly half of $1 billion. Samumed said Monday that it had raised $438 million in an A-6 Round of equity, ...

If you Google Osman Kibar's name you'll find pictures of him playing poker. It's not that he was ever a serious player--just that in 2006 he won the first poker tournament he ever played in and then, ...

SAN FRANCISCO--November 9, 2015--At the American College of Rheumatology (ACR) Annual Meeting, Samumed unveiled groundbreaking pre-clinical and clinical research that demonstrated successful ...

$12 billion biotech Samumed on Wednesday is presenting data from a clinical trial looking at how one of its lead drugs works in patients with osteoarthritis. The results, which Samumed plans to use to ...